证券代码：000516 证券简称：国际医学 公告编号：2026-004 西安国际医学投资股份有限公司 2025年度业绩预告 本次业绩预告未经注册会计师预审计。公司就本次业绩预告与为公司提供 年度审计服务的会计师事务所签字注册会计师进行了预沟通，双方在本次业绩 预告方面不存在分歧。 1 三、业绩变动原因说明 报告期内，公司受市场波动、DRG支付政策改革等行业动态调整影响，营业 收入同比下降。公司采取调整业务结构，实施降本增效等措施并持续改善经营 成效，第四季度亏损幅度收窄，但营业收入总规模尚未能覆盖运营成本和期间 费用。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1.业绩预告期间：2025年1月1日至2025年12月31日 2.业绩预告情况：预计净利润为负值 | 3.业绩预告情况表 | | --- | | 项 目 | 本报告期 | 上年同期 | | --- | --- | --- | | 归属于上市公司股东 | 亏损：31,500 万元～29,500 万元 | 亏损 25,412.85 万元 | | 的净利润 | 比上年同期下降：23 ...

国际医学公告，预计2025年度净利润亏损3.15亿元～2.95亿元，上年同期亏损2.54亿元。报告期内，公 司受市场波动、DRG支付政策改革等行业动态调整影响，营业收入同比下降。公司采取调整业务结 构，实施降本增效等措施并持续改善经营成效，第四季度亏损幅度收窄，但营业收入总规模尚未能覆盖 运营成本和期间费用。 ...

中新网三亚1月23日电 (张月和 黎婉玲)为期三天的"零关税畅拍·珠耀三亚"海南自贸港珠宝(大溪地黑珍 珠)创新竞价会23日在三亚崖州湾科技城海润黄金珠宝产业园启幕。 广东省珠宝玉石交易中心有限责任公司董事长黄勇受访时说，此次竞价会以零关税珍珠为突破口，搭建 起了粤琼珠宝产业政策对接、资源互通、模式创新的新平台。粤琼两地未来可在三方面深化珠宝产业合 作：一是开展常态化活动并拓展品类，打造粤琼珠宝特色IP；二是共建"原料进口—保税加工—品牌运 营—跨境销售"一体化链条；三是探索保税贸易、跨境电商、文旅融合、金融赋能等新业态，推动合作 从"要素对接"向"生态共建"升级。 海南海润珍珠股份有限公司董事长张士忠表示，此次创新竞价会为国际珠宝原料交易提供了可复制、可 推广的样本，有效推动珍珠原料向高附加值珠宝产品转化，促进产业链上下游协同升级。未来，海润珍 珠将持续深耕珍珠原料进口交易领域，常态化拓展竞价会等创新交易模式，进一步强化原产地直供优 势。同时，深化海南自贸港政策应用，依托海润黄金珠宝产业园的平台资源，吸引更多产业链优质资源 集聚，助力海南打造具有国际竞争力的珠宝产业集群。(完) 此次竞价会以"原产地直供+创 ...

Core Viewpoint - The company is actively focusing on modern frontier medical technologies, including smart healthcare and brain-computer interfaces, as indicated by its recent patent application in the field [1]. Group 1: Company Developments - The company has applied for a patent related to a DAC-GAN model construction method and its application in breast MR imaging [1]. - The primary function of the patented technology is to acquire and process breast MR image datasets, constructing a DAC-GAN model to predict breast MR images [1].

Core Viewpoint - The company has been deeply engaged in the healthcare industry for over 20 years, providing comprehensive healthcare services from life conception to health management, medical services to rehabilitation and elderly care [1] Group 1: Business Focus - The company is actively exploring diversified service models, including home visits, continuous care, and internet healthcare, to meet the personalized healthcare needs of different patients [1] - Future business expansion will focus on high-level medical services and will include life health management, integrated medical and elderly care, and smart health management to better serve the aging population [1]

Core Viewpoint - The company has received approval for a private placement aimed at funding specific projects, including a smart healthcare initiative and the second phase of a proton therapy center, while also addressing liquidity needs [2] Group 1: Fundraising Details - The private placement has been approved by the company's 13th Board of Directors at its 9th meeting and the second extraordinary shareholders' meeting of 2025 [2] - The raised funds will be allocated specifically for the smart healthcare project, the second phase of the proton therapy center, and to supplement working capital [2] - According to the regulations on fundraising by listed companies, the use of raised funds must be strictly adhered to, and any significant adjustments to the planned use must follow legal procedures [2]

国际医学（000516.SZ）1月22日在投资者互动平台表示，您好，感谢您对公司的关注。公司持有平阳融 泰高德股权投资合伙企业17.5439%的股权，平阳融泰高德股权投资合伙企业持有蓝箭航天0.6889%的股 份。公司目前尚无在太空中研发医疗药品的计划。谢谢！ （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：蓝箭航天是中国领先的商业航天企业，启动科创板IPO 冲刺"商业航天第一股" 传闻国际医学是否通过平阳融泰高德股权投资合伙企业（有限合伙）持有蓝箭 航天的股份，正式进入商业航天领域，后期是否有在太空研发医疗药品的计划？ ...

Group 1 - The company holds a 17.5439% stake in Pingyang Rongtai Gaode Equity Investment Partnership, which in turn owns 0.6889% of Blue Arrow Aerospace [1] - The company currently has no plans to develop medical drugs in space [1]

Market Overview - The medical services sector increased by 0.18% on January 21, with Nanmo Biology leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] Top Gainers in Medical Services - Nanmo Biology (688265) closed at 49.79, up 7.01% with a trading volume of 20,000 shares and a transaction value of 98.02 million [1] - Hite Biology (300683) closed at 29.67, up 5.74% with a trading volume of 107,800 shares and a transaction value of 32.2 million [1] - Dean Diagnostics (300244) closed at 26.46, up 5.59% with a trading volume of 796,300 shares and a transaction value of 2.13 billion [1] - ST Zhongzhu (600568) closed at 2.64, up 5.18% with a trading volume of 376,500 shares and a transaction value of 9.81 million [1] - Tongce Medical (600763) closed at 46.51, up 4.99% with a trading volume of 198,600 shares and a transaction value of 911 million [1] Top Losers in Medical Services - Digital Human (920670) closed at 18.72, down 4.44% with a trading volume of 74,500 shares and a transaction value of 143 million [2] - Hongbo Pharmaceutical (301230) closed at 46.36, down 1.88% with a trading volume of 131,200 shares and a transaction value of 614 million [2] - Chengda Pharmaceutical (301201) closed at 41.39, down 1.76% with a trading volume of 36,600 shares and a transaction value of 153 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 50.51 million from institutional investors, while retail investors experienced a net outflow of 375 million [2] - The sector's overall capital flow indicates a strong interest from institutional and speculative investors, with retail investors pulling back [2][3] Notable Capital Inflows - Sanbo Brain Science (301293) had a net inflow of 91.48 million, representing 9.03% of its total capital [3] - Tongce Medical (600763) saw a net inflow of 83.46 million, accounting for 9.16% of its total capital [3] - BGI Genomics (300676) recorded a net inflow of 51.81 million, which is 8.37% of its total capital [3]

Core Viewpoint - International Medical (000516) experienced a significant decline in stock price, closing at 5.19 yuan on January 16, 2026, down 6.82% with a trading volume of 1.966 million hands and a turnover of 1.033 billion yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, International Medical reported a main revenue of 2.995 billion yuan, a year-on-year decrease of 16.94% [3] - The net profit attributable to shareholders was -294 million yuan, down 38.45% year-on-year, while the net profit excluding non-recurring items was -312 million yuan, a decline of 41.94% [3] - In Q3 2025, the company recorded a single-quarter main revenue of 961 million yuan, a year-on-year decrease of 18.95%, and a net profit attributable to shareholders of -129 million yuan, down 234.24% year-on-year [3] - The company's debt ratio stands at 68.8%, with investment income of 20.7586 million yuan and financial expenses of 111 million yuan, resulting in a gross margin of 6.59% [3] Group 2: Market Activity - On January 16, 2026, the net outflow of main funds was 27.5033 million yuan, accounting for 2.66% of the total turnover, while retail investors saw a net inflow of 52.6397 million yuan, representing 5.1% of the total turnover [1] - In the financing aspect, the company had a financing buy of 96.5524 million yuan and a financing repayment of 82.2475 million yuan, resulting in a net financing increase of 14.3049 million yuan [2] - The total financing and securities balance is reported at 394 million yuan [2] Group 3: Analyst Ratings - Over the past 90 days, two institutions have given a rating of "buy" for International Medical, with an average target price of 5.5 yuan [4]